Abstract:Background: Patients undergoing percutaneous coronary intervention react differently to antiplatelet drugs. Those with low responsiveness to clopidogrel have a higher risk of cardiac ischemic events. The goal of this study is to conduct a head-to-head comparison of the safety and effectiveness of intensified antiplatelet therapies (either double-dose clopidogrel [DOUBLE] or adjunctive cilostazol [TRIPLE]) and conventional strategy (STANDARD) in patients after percutaneous coronary intervention. Methods: In this single-center, randomized, controlled trial, we used thromboelastography, a platelet function test, to select 1078 patients undergoing percutaneous coronary intervention at high thrombotic risk and compared the intensified antiplatelet therapies with standard antiplatelet therapy. The primary outcome was the incidence of major adverse cardiac and cerebrovascular events at 18 months after percutaneous coronary intervention, defined as a composite of all-cause death, myocardial infarction, target vessel revascularization, or stroke. Bleeding Academic Research Consortium defined bleeding complications (types 1, 2, 3, or 5) were the safety end points. Results: The primary end point occurred in 52 patients (14.4%) in the STANDARD group, 38 patients (10.6%) in the DOUBLE group, and 30 patients (8.5%) in the TRIPLE group (hazard ratio, 0.720; 95% confidence interval, 0.474–1.094, DOUBLE versus STANDARD; hazard ratio, 0.550; 95% confidence interval, 0.349–0.866, TRIPLE versus STANDARD). No significant difference in the rates of major bleeding (Bleeding Academic Research Consortium grade≥3) was found in the DOUBLE group (3.34% versus 1.93% in STANDARD, P =0.133) and the TRIPLE group (2.53% versus 1.93% in STANDARD, P =0.240). The rate of Bleeding Academic Research Consortium–defined minor bleeding increased in the DOUBLE group (27.4% versus 20.3% in STANDARD, P =0.031), but not in the TRIPLE group (23.6% versus 20.3% in STANDARD, P =0.146). Conclusions: In patients with low responsiveness to clopidogrel, as measured by thromboelastography, the intensified antiplatelet strategies with adjunctive use of cilostazol significantly improved the clinical outcomes without increasing the risk of major bleeding. Decreased trend of negative outcomes could be observed in patients with double dosage of clopidogrel, but the difference was not significant. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01779401.

The Effectiveness and Safety of Triple‐Antiplatelet Treatment Based on Cilostazol for Patients Receiving Percutaneous Coronary Intervention: A Meta‐Analysis

Cilostazol in Addition to Aspirin and Clopidogrel Improves Long-Term Outcomes after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndromes: A Randomized, Controlled Study

Effects of Triple Antiplatelet Therapy on Patients Undergone Coronary Artery Stenting

Long-term effect of triple antiplatelet therapy for diabetic patients after percutaneous coronary intervention

Efficacy and Safety of Cilostazol-Based Triple Antiplatelet Therapy Compared with Clopidogrel-Based Dual Antiplatelet Therapy in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Multicenter, Randomized, Open-Label, Phase 4 Trial

Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients with High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial.

Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reducing the Risk of Cardiac Events and Restenosis after Drug-Eluting Stent Implantation: A Meta-Analysis

Effect of Different Doses of Cilostazol Intensive Antiplatelet Therapy on the Patients with High On-treatment Platelet Reactivity after Coronary Stent Implantation

Comparison of Cilostazol Versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke Who Underwent Intracranial or Extracranial Artery Stent Implantation

Efficacy and Safety of Antithrombotic Regimens after Coronary Intervention in Patients on Oral Anticoagulation: Traditional and Bayesian Meta-Analysis of Clinical Trials.

The Effects of Post Coronary Stenting Triple Antiplatelet Therapies on Platelet Functions

Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials

The Efficacy and Safety of Cilostazol As an Alternative to Aspirin in Chinese Patients with Aspirin Intolerance after Coronary Stent Implantation: a Combined Clinical Study and Computational System Pharmacology Analysis

P2Y12 Inhibitor vs Aspirin Monotherapy Following Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Updated Meta-Analysis

Antithrombotic Regimens for Patients Taking Oral Anticoagulation After Coronary Intervention: A Meta-analysis of 16 Clinical Trials and 9185 Patients.

Comparison of the Efficacy of Dual Antiplatelet Treatment at Different Treatment Times in Patients with High Bleeding Risk after PCI: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Effectiveness of Combination of Cilostazol and Aspirin in Preventing Thrombosis after Interventional Neuroradiology Procedures

A randomized trial of cilostazol versus ticlopidine for anti-platelet therapy after coronary artery stenting for prevention of restenosis

Dual and triple antithrombotic pharmacotherapy i n patients with coronary heart disease complicated with atrial fibrillation after percutaneous coronary intervention

RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome.

[A Clinical Trial of Using Antiplatelet Therapy to Prevent Restenosis Following Peripheral Artery Angioplasty and Stenting].